PRTA - Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
2024-02-15 23:53:08 ET
Prothena Corporation plc (PRTA)
Q4 2023 Earnings Conference Call
February 15, 2023 4:30 PM ET
Company Participants
Mark Johnson - Vice President of Investor Relations
Gene Kinney - President and Chief Executive Officer
Hideki Garren - Chief Medical Officer
Tran Nguyen - Chief Financial Officer and Chief Strategy Officer
Brandon Smith - Chief Operating Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Jay Olson - Oppenheimer
Neena Bitritto-Garg - Citi
Yasmeen Rahimi - Piper Sandler
Rudy Li - Leerink Partners
Michael Yi - Jefferies
Jason Butler - JMP Securities
Ananda Ghosh - H.C. Wainwright
Presentation
Operator
Good day ladies and gentlemen and welcome to the Prothena Biosciences Fourth Quarter and Full Year 2023 Financial Results Conference Call. My name is Crysta and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today’s call. [Operator Instructions]
I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at Prothena. Please proceed.
Mark Johnson
Thank you, operator. Good afternoon, everyone and welcome to today’s call to review Prothena's business progress, fourth quarter and full year 2023 financial results and our 2024 financial guidance. Please review the press release we issued earlier today, which is available on our website at prothena.com and is also attached to a Form 8-K filed today with the SEC. In addition, we are using supplemental slides which are available on our Investor website Events and Presentation section.
On today's call, Dr. Gene Kinney, our President and Chief Executive Officer will provide opening remarks including an overview of Prothena's corporate and development strategy; then Brandon Smith, our Chief Operating Officer will provide an update on our pre-commercial progress for our wholly-owned Birtamimab program which is in Phase 3 for the treatment of patients with MAYO Stage IV AL Amyloidosis. Hideki Garren, our Chief Medical Officer will provide an update on our ongoing clinical programs. Tran Nguyen, our Chief Financial Officer and Chief Strategy Officer, will then discuss our 2023 financial results and 2024 financial guidance before turning it back to Gene for closing remarks at which point we will open the call up for a Q&A session.
Before we begin, I would like to remind you that during today's presentation, we will be making forward-looking statements that are subject to certain risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements. For a discussion of the risks and uncertainties associated with our forward-looking statements, please see our press release issued today, as well as our most recent filings with the SEC. We disclaim any obligation to update our forward-looking statements....
Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript